Related references
Note: Only part of the references are listed.PDGFRβ-targeted TRAIL specifically induces apoptosis of activated hepatic stellate cells and ameliorates liver fibrosis
Rui Li et al.
APOPTOSIS (2020)
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases
Boris Hinz et al.
NATURE REVIEWS RHEUMATOLOGY (2020)
Liver-Targeted siRNA Lipid Nanoparticles Treat Hepatic Cirrhosis by Dual Antifibrotic and Anti-inflammatory Activities
Jinfang Zhang et al.
ACS NANO (2020)
CD248: A therapeutic target in cancer and fibrotic diseases
Beverly A. Teicher
Oncotarget (2019)
Golgi Apparatus-Targeted Chondroitin-Modified Nanomicelles Suppress Hepatic Stellate Cell Activation for the Management of Liver Fibrosis
Jingwen Luo et al.
ACS NANO (2019)
Targeting cardiac fibrosis with engineered T cells
Haig Aghajanian et al.
NATURE (2019)
Shared and distinct mechanisms of fibrosis
Joerg H. W. Distler et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019
Bedair Dewidar et al.
CELLS (2019)
Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo
Qinghua Li et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
TGF-β: Master regulator of inflammation and fibrosis
Alastair G. Stewart et al.
RESPIROLOGY (2018)
Targeting CCl4-Induced Liver Fibrosis by RNA Interference-Mediated Inhibition of Cyclin E1 in Mice
Joerg-Martin Bangen et al.
HEPATOLOGY (2017)
Hepatic stellate cells as key target in liver fibrosis
Takaaki Higashi et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism
Annika Wilhelm et al.
GUT (2016)
Systemic PEGylated TRAIL Treatment Ameliorates Liver Cirrhosis in Rats by Eliminating Activated Hepatic Stellate Cells
Yumin Oh et al.
HEPATOLOGY (2016)
Clinical Advancements in the Targeted Therapies against Liver Fibrosis
Ruchi Bansal et al.
MEDIATORS OF INFLAMMATION (2016)
TGF-β: the master regulator of fibrosis
Xiao-ming Meng et al.
NATURE REVIEWS NEPHROLOGY (2016)
Hepatic stellate cell-expressed endosialin balances fibrogenesis and hepatocyte proliferation during liver damage
Carolin Mogler et al.
EMBO MOLECULAR MEDICINE (2015)
High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers
Ingmar Mederacke et al.
NATURE PROTOCOLS (2015)
Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature
Katherine Rybinski et al.
ONCOTARGET (2015)
Therapy for Fibrotic Diseases: Nearing the Starting Line
Scott L. Friedman et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization
Rebecca G. Bagley et al.
MICROVASCULAR RESEARCH (2008)
CD248/endosialin is dynamically expressed on a subset of stromal cells during lymphold tissue development, splenic remodeling and repair
Sian Lax et al.
FEBS LETTERS (2007)
Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium
JR MacFadyen et al.
FEBS LETTERS (2005)
Regulation of PDGF and its receptors in fibrotic diseases
JC Bonner
CYTOKINE & GROWTH FACTOR REVIEWS (2004)
Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium
S Christian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
